Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A09451 | Pages: 183 | Charts: 63 | Tables: 64 |
U.S. pain management drugs market Insight 2022-2031
The U.S. pain management drugs market size was valued at $25,174.29 Million in 2021, and is projected to reach $34,824.24 Million by 2031, registering a CAGR of 3.3% from 2022 to 2031. Pain is defined as an unpleasant sensory and emotional experience conveyed to the brain by sensory neurons, which causes actual or potential tissue damage. The length of the pain can range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. Pain management is a medical approach that draws on disciplines in science and alternative healing to study the prevention, diagnosis, and treatment of pain.
“The U.S. pain management drugs market was hampered during the lockdown period owning to disruption in supply chain of pain medications. During pandemic, decline in surgeries and delay in approval of various novel pain medications hampered the growth of U.S. pain management market.”
Historical Overview
The market was analyzed qualitatively and quantitatively from 2021-2031. The U.S. pain management drugs market grew at a CAGR of around 3.3% during 2022-2031. Most of the growth during this period was derived from the U.S. owing to factors such as effective distribution network for pain management drugs, awareness regarding pain disorders and new drug approvals in the U.S. contributes to growth of market.
Market Dynamics
Growth & innovations in the pharmaceutical industry for the manufacturing of pain-relieving drugs owing to massive pool of health-conscious consumers creates an opportunity for the U.S. pain management drugs market. Also, the growth of the U.S. pain management drugs market is expected to be driven by rise in pain disorders, availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of chronic diseases cases in geriatric population, and surge in demand for effective pain medicines with less side effects. Furthermore, the healthcare industry in the U.S. is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and development of the medical tourism industry in various cities of the U.S.
As elderly people experience chronic pain due to joint disorders, various surgeries various pain medications are prescribed, which contributes to growth of U.S. pain management drugs market. In U.S., rise in number of diabetic neuropathies is observed, which leads to pain, thus, driving the market growth. For instance, according to an article published in National Library of Medicine 2021, increase in diabetic neuropathic cases was observed from 30 million in 2019 to 85 million in U.S. which drives the market growth.
Further, increase in incidence of sport injuries is expected to fuel the growth of market. For instance, according to article published in National Library of Medicine 2021, stated that 3.5 million injuries were reported in 2020 with 21% being brain injuries. In addition, rise in prevalence of low back pain cases in adults is increasing contributing to market growth. For instance, according to article published in Springer 2022, stated that 54% adults suffer from back pain with 24 – 80% reoccurrence pain disorder in one year.
In addition, surge in government spending on pain management treatment further fuels the market growth. For instance, according to Journal of Pain 2020, spending on chronic pain in the U.S. in one year is usually $635 billion. Furthermore, various organizations along with the government provide funding for pain management, which is anticipated to contribute to market growth. For instance, according to article published, Congressionally Directed Medical Research Programs 2022, stated that funding of $250,000 is provided to support and promote innovative, high-impact research for the development and management of chronic pain.
Further, rise in prevalence of muscle strain disorders such as neck pain, shoulder, groin pain, and hamstring also require pain medications. For instance, according to article published in National Library of Medicine 2021, patients with muscle strain are prescribed NSAIDs and acetaminophen for 2 to 4 weeks, depending upon the pain condition. Thus, such muscle disorders fuel the growth of the market. In addition, rise in prevalence of acute appendicitis in the U.S. is anticipated to contribute to growth of pain management drugs market. For instance, according to article published in Single care 2021, stated that around 7 in 100 people in U.S., will experience acute appendicitis at some point and is usually common in age between 10 to 30.
Various organizations along with government are counselling people regarding the pain disorders with proper management. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding dose and frequency of pain medication has contributed to growth of this U.S. pain management drugs market. Moreover, increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for pain disorders among the general population are expected to fuel their adoption in the near future.
Further, availability of various alternative therapies like pain management devices chiropractic manipulation and acupuncture is anticipated to hamper the growth of market. In addition, various side effects of drugs, misuse and habit-forming drugs restrain the market growth. Furthermore, various new advancements like innovative technologies and strategies to formulate drugs which are abuse-deterrent and having long duration effect provide lucrative opportunities to the market players.
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The U.S. pain management drugs market experienced a decline in 2021 due to global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain of pain drugs across various end-user industries like hospitals and pharmacies.
However, the market is anticipated to witness recovery in 2021, and show stable growth for U.S. pain management drugs market in the coming future. This is attributed to the increase in adoption of various pain medications with less side effects, rise in number of pending surgeries, increase diabetes disorders, proper counselling for post operative pain conditions and drug approvals for new pain disorders, drive the market growth.
Segmental Overview
The U.S. pain management drugs market is segmented into drug class, indication, and type of pain. On the basis of drug class, the market is categorized into non-steroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. Further, it is subdivided into drug class for each indication. On the basis of pain type, the market is segmented bifurcated into chronic and acute pain.
By drug class: depending on drug class, the market is bifurcated into non-steroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. The opioids segment exhibited highest growth in 2021 and is expected to remain dominant during the forecast period, owing to use of these medications for major pain conditions and awareness regarding opioids.
By indication: On the basis of indication, the market is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. The postoperative pain segment dominated the market in 2021. This is attributed to rise in number of lifesaving surgeries contributing to growth of the market. Moreover, cancer pain segment is projected to register a highest CAGR during the forecast period, owing to rise in prevalence of cancer cases in U.S.
By pain type: On the basis of pain type, the market is segmented into chronic pain and acute pain. The chronic pain segment exhibited highest revenue and is projected to register highest CAGR in 2021, owing to higher prevalence of chronic pain conditions like back pain, pain related to cardiovascular diseases and rise in number of geriatric populations suffering from chronic pain in the U.S.
Presence of several major players, such as Pfizer Inc, Viatris (Mylan N.V.), Eli Lilly and Company, and advancement in manufacturing technology for pain medications in the U.S., drive the growth of the market. In addition, various private organizations organize educating camps for effective pain management treatment across the U.S., marked the growth of this market. For instance, in August 2022, Myovant Sciences, and Pfizer received U.S. FDA Approval for Myfembree, a once-daily treatment for the management of moderate to severe pain associated with endometriosis.
Presence of well-established healthcare infrastructure, and rise in adoption rate of various new pain medications are expected to drive the market growth. Furthermore, agreement as key strategy adopted by the key players in this U.S., further boost the growth of the market. For instance, in May 2019, Eli Lilly announced a licensing agreement to acquire exclusive U.S. rights for CNTX-0290 from Centrexion Therapeutics Corporation. Centrexion mainly focused on developing non-opioid, non-addictive therapeutics for treatment of chronic pain through research and development initiatives that will lead to important clinical advances.
[DRUGCLASSGRAPH]
U.S. is expected to grow at the CAGR of 3.3% during the forecast period. The market growth in U.S., is attributable to presence of key players in the region. Moreover, rise in adoption of various formulations for pain management drive the growth of the market. U.S. has high number cancer cases detected, and high percentage of people experience cancer pain which fuels the growth of the market. U.S. offers profitable opportunities for key players operating in the pain management drugs market, owing to the growing infrastructure of industries, rising in spending for pain disorders, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the U.S. provides great opportunity for new entrants in this region.
Competition Analysis
Competitive analysis and profiles of the major players in the U.S. pain management drugs market, such as Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. Major players have adopted agreement, product approval, collaboration and partnerships as key developmental strategies to improve the product portfolio of the U.S. pain management drugs market.
[INDICATIONGRAPH]
Some examples of agreement in the market
In March 2019, Merck & Co. announced an agreement with King’s College London (KCL) to investigate a new class of painkillers that could provide an alternative to opioids and their dangerous side-effects.
Some examples of collaboration in the market
In January 2019, Purdue Pharma L.P. and Ocular Therapeutix announce initiation of collaborative research activities to evaluate innovative formulations for non-opioid treatments for pain.
Product approval in the market
In December 2021, Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis related arthritis and psoriatic arthritis.
Partnership in the market
In January 2019, Purdue Pharma L.P. and Alivio therapeutics enter into partnership to advance ALV-107, a non-opioid interstitial cystitis/bladder pain syndrome treatment.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.1.1.Top investment pockets
3.2.Porters five forces analysis
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Rise in incidences of chronic diseases
3.3.1.2.Increase in geriatric population
3.3.1.3.Favorable regulatory scenario
3.3.2.Restraints
3.3.2.1.Availability of alternative therapies
3.3.2.2.Drug exploitation
3.3.3.Opportunity
3.3.3.1.Advancements in drug development
3.3.4.Impact Analysis
3.4.COVID-19 impact analysis for U.S. pain management drugs market
CHAPTER 4:U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.6.Antidepressants
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast
CHAPTER 5:U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast
5.3.Neuropathic pain
5.3.1.Market size and forecast
5.4.Cancer pain
5.4.1.Market size and forecast
5.5.Chronic back pain
5.5.1.Market size and forecast
5.6.Post-operative pain
5.6.1.Market size and forecast
5.7.Migraine
5.7.1.Market size and forecast
5.8.Fibromyalgia
5.8.1.Market size and forecast
5.9.Bone fracture
5.9.1.Market size and forecast
5.10.Muscle sprain/strain
5.10.1.Market size and forecast
5.11.Acute appendicitis
5.11.1.Market size and forecast
5.12.Others
5.12.1.Market size and forecast
CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast
6.3.Acute pain
6.3.1.Market size and forecast
CHAPTER 7:COMPETITION LANDSCAPE
7.1.Top winning strategies
7.2.Competitive dashboard
7.3.Competitive heatmap
7.4.Product mapping
7.5.Top player positioning
7.6.Key developments
7.6.1.Agreement
7.6.2.Collaboration
7.6.3.Partnership
7.6.4.Product Approval
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Key Executives
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business performance
8.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
8.2.1.Company overview
8.2.2.Key Executives
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.2.6.Business performance
8.3.ELI LILY AND COMPANY
8.3.1.Company overview
8.3.2.Key executives
8.3.3.Company snapshot
8.3.4.Operating business segment
8.3.5.Product portfolio
8.3.6.Business performance
8.3.7.Key strategic moves and developments
8.4.GLAXOSMITHKLINE PLC (GSK)
8.4.1.Company overview
8.4.2.Key Executives
8.4.3.Company snapshot
8.4.4.Operating business segments
8.4.5.Product portfolio
8.4.6.Business performance.
8.4.7.Key strategic moves and developments
8.5.JOHNSON & JOHNSON
8.5.1.Company overview
8.5.2.Key Executives
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.Business performance
8.6.MERCK & CO., INC.
8.6.1.Company overview
8.6.2.Key Executives
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.6.6.Business performance
8.6.7.Key strategic moves and developments
8.7.VIATRIS INC. (MYLAN NV)
8.7.1.Company overview
8.7.2.Key Executives
8.7.3.Company snapshot
8.7.4.Operating business segment
8.7.5.Product portfolio
8.7.6.Business performance
8.8.NOVARTIS INTERNATIONAL AG
8.8.1.Company overview
8.8.2.Key Executives
8.8.3.Company snapshot
8.8.4.Operating business segment
8.8.5.Product portfolio
8.8.6.Business performance
8.8.7.Key strategic moves and developments
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Key Executives
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.9.6.Business performance
8.9.7.Key strategic moves and developments
8.10.PURDUE PHARMA L.P.
8.10.1.Company overview
8.10.2.Key Executives
8.10.3.Company snapshot
8.10.4.Operating business segment
8.10.5.Product portfolio
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2021–2031 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 03.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 04.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 05.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 06.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 07.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 08.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 09.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 10.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 11.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 12.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 13.U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2021-2031 ($MILLION)
TABLE 14.ABBOTT: KEY EXECUTIVES
TABLE 15.ABBOTT: COMPANY SNAPSHOT
TABLE 16.ABBOTT: OPERATING SEGMENT
TABLE 17.ABBOTT: PRODUCT PORTFOLIO
TABLE 18.ABBOTT: NET SALES, 2019–2021
TABLE 19.BOEHRINGER INGELHEIM: KEY EXECUTIVES
TABLE 20.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 21.BOEHRINGER INGELHEIM : OPERATING SEGMENTS
TABLE 22.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 23.BOEHRINGER INGELHEIM: NET SALES, 2019–2021
TABLE 24.ELI LILLY: KEY EXECUTIVES
TABLE 25.ELI LILLY COMPANY SNAPSHOT -
TABLE 26.ELI LILLY:OPERATING SEGMENT -
TABLE 27.ELI LILLY: PRODUCT PORTFOLIO
TABLE 28.ELI LILLY: NET SALES, 2019–2021
TABLE 29.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 30.GSK: KEY EXECUTIVES
TABLE 31.GSK: COMPANY SNAPSHOT
TABLE 32.GSK: OPERATING SEGMENT
TABLE 33.GSK: PRODUCT PORTFOLIO
TABLE 34.GSK: NET SALES, 2019–2021
TABLE 35.J&J: KEY EXECUTIVES
TABLE 36.J&J: COMPANY SNAPSHOT
TABLE 37.J&J: OPERATING SEGMENT
TABLE 38.J&J: PRODUCT PORTFOLIO
TABLE 39.J&J: NET SALES, 2019–2021
TABLE 40.MERCK: KEY EXECUTIVES
TABLE 41.MERCK: COMPANY SNAPSHOT
TABLE 42.MERCK: OPERATING SEGMENTS
TABLE 43.MERCK.: PRODUCT PORTFOLIO
TABLE 44.MERCK: NET SALES, 2019–2021
TABLE 45.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 46.VIATRIS: KEY EXECUTIVES
TABLE 47.VIATRIS: COMPANY SNAPSHOT
TABLE 48.VIATRIS: OPERATING SEGMENT
TABLE 49.VIATRIS: PRODUCT PORTFOLIO
TABLE 50.VIATRIS: NET SALES, 2019–2021
TABLE 51.NOVARTIS: KEY EXECUTIVES
TABLE 52.NOVARTIS: COMPANY SNAPSHOT
TABLE 53.NOVARTIS: OPERATING SEGMENT
TABLE 54.NOVARTIS: PRODUCT PORTFOLIO
TABLE 55.NOVARTIS: NET SALES, 2019–2021
TABLE 56.PFIZER: KEY EXECUTIVES
TABLE 57.PFIZER: COMPANY SNAPSHOT
TABLE 58.PFIZER: OPERATING SEGMENT
TABLE 59.PFIZER: PRODUCT PORTFOLIO
TABLE 60.PFIZER: NET SALES, 2019–2021
TABLE 61.PURDUE: KEY EXECUTIVES
TABLE 62.PURDUE: COMPANY SNAPSHOT
TABLE 63.PURDUE: OPERATING SEGMENT
TABLE 64.PURDUE: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.U.S. PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.MODERATE THREAT OF SUBSTITUTION
FIGURE 07.MODERATE THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSIS, U.S. PAIN MANAGEMENT DRUGS MARKET
FIGURE 10.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2021-2031 ($MILLION)
FIGURE 11.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC, 2021-2031 ($MILLION)
FIGURE 12.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS, 2021-2031 ($MILLION)
FIGURE 13.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE AGENTS, 2021-2031 ($MILLION)
FIGURE 14.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS, 2021-2031 ($MILLION)
FIGURE 15.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2021-2031 ($MILLION)
FIGURE 16.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS, 2021-2031 ($MILLION)
FIGURE 17.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN, 2021-2031 ($MILLION)
FIGURE 18.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN, 2021-2031 ($MILLION)
FIGURE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN, 2021-2031 ($MILLION)
FIGURE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN, 2021-2031 ($MILLION)
FIGURE 21.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN, 2021-2031 ($MILLION)
FIGURE 22.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2021-2031 ($MILLION)
FIGURE 23.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2021-2031 ($MILLION)
FIGURE 24.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2021-2031 ($MILLION)
FIGURE 25.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE BY DRUG CLASS, 2021-2031 ($MILLION)
FIGURE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2021-2031 ($MILLION)
FIGURE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2021-2031 ($MILLION)
FIGURE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2021-2031 ($MILLION)
FIGURE 29.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2021-2031 ($MILLION)
FIGURE 30.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2021-2031 ($MILLION)
FIGURE 31.TOP WINNING STRATEGIES, BY YEAR, 2019-2022
FIGURE 32.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2022
FIGURE 33.TOP WINNING STRATEGIES, BY COMPANY, 2019-2022
FIGURE 34.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 35.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 36.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 37.TOP PLAYER POSITIONING
FIGURE 38.ABBOTT: NET SALES, 2019–2021 ($MILLION)
FIGURE 39.ABBOTT: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 40.ABBOTT: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 41.BOEHRINGER INGELHEIM: NET SALES, 2019–2021 ($MILLION)
FIGURE 42.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 43.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 44.ELI LILLY: NET SALES, 2019–2021 ($MILLION)
FIGURE 45.ELI LILLY: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 46.GSK: NET SALES, 2019–2021 ($MILLION)
FIGURE 47.GSK: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 48.GSK: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 49.J&J: NET SALES, 2019–2021 ($MILLION)
FIGURE 50.J&J: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 51.J&J: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 52.MERCK & CO., INC.: NET SALES, 2019–2021 ($MILLION)
FIGURE 53.MERCK: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 54.MERCK: REVENUE SHARE, BY REGION, 2021 (%)
FIGURE 55.VIATRIS NET SALES, 2019–2021 ($MILLION)
FIGURE 56.VIATRIS: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 57.VIATRIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 58.NOVARTIS: NET SALES, 2019–2021 ($MILLION)
FIGURE 59.NOVARTIS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 60.NOVARTIS: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 61.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 62.PFIZER: REVENUE SHARE, BY SEGMENT, 2021 (%)
FIGURE 63.PFIZER: REVENUE SHARE, BY REGION, 2021 (%)